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Abstract 
The selection of liver transplant candidates with hepatocellular carcinoma (HCC) is 
currently validated based on Milan criteria. The use of extended criteria has remained a 
matter of debate, mainly because of the absence of prospective validation. The present 
prospective study recruited patients according to the previously proposed Total Tumor 
Volume (TTV ≤115 cm
3
)/ alpha fetoprotein (AFP ≤400 ng/ml) score. Patients with AFP 
>400 ng/ml were excluded, and as such the Milan group was modified to include only 
patients with AFP <400 ng/ml; these patients were compared to patients beyond Milan, 
but within TTV/AFP. From January 2007 to March 2013, 233 patients with HCC were 
listed for liver transplantation. Of them, 195 patients were within Milan, and 38 beyond 
Milan but within TTV/AFP. The average follow-up from listing was 33,9 ±24,9 months. 
The risk of drop-out was higher for patients beyond Milan but within TTV/AFP (16/38, 
42,1%), than for patients within Milan (49/195, 25,1%, p=0,033). In parallel, intent-to-
treat survival from listing was lower in the patients beyond Milan (53,8% vs. 71,6% at 
four years, p<0,001). After a median waiting time of 8 months, 166 patients were 
transplanted, 134 patients within Milan criteria, and 32 beyond Milan but within 
TTV/AFP. They demonstrated acceptable and similar recurrence rates (4,5% vs. 9,4%, 
p=0,138) and post-transplant survivals (78,7% vs. 74,6% at four years, p=0,932). 
Conclusion: Based on the present prospective study, HCC liver transplant candidate 
selection could be expanded to the TTV (≤115 cm
3
)/ AFP (≤400 ng/ml) criteria in centers 
with at least 8-month waiting time. An increased risk of drop-out on the waiting list can 
be expected but with equivalent and satisfactory post-transplant survival.
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Introduction 
Liver transplantation is the most effective treatment for patients with early non-resectable 
hepatocellular carcinoma (HCC). However, some 5%-15% of patients experience a post-
transplant recurrence, and candidate selection appears to be the most effective action for 
its prevention (1, 2). Milan criteria have been widely accepted for the selection of HCC 
patients for liver transplantation (3). With the use of Milan criteria, post-transplant 
survival rates of 75%-95% at two years and 70%-80% at five-years have been repeatedly 
observed, which represents the basis for use of Milan criteria as a gold standard when 
exploring new criteria (1, 3, 4). An international panel of experts also agreed that a 
modest expansion of the number of potential candidates could be considered on the basis 
of studies showing similar survivals for select patients outside Milan criteria (3). 
In recent years, a wide range of expanded criteria have been proposed, including the 
externally validated University of California San Francisco (UCSF) criteria (one HCC 
≤6·5 cm or ≤3 HCCs ≤4·5 cm and total tumor diameter ≤8 cm) and the registry-based up-
to-seven score (size of largest HCC + number of HCCs ≤7) (1, 5-8). However, none of 
these criteria has reached wide acceptance thus far, mainly due to a lack of robust 
prospective validation. 
The potential for candidate selection based on a composite of the total tumor volume 
(TTV ≤115 cm
3
) and AFP ≤400 ng/ml without macrovascular invasion or extrahepatic 
disease has been recently explored. This score has been designed based on single-center, 
multi-center and registry based (SRTR) studies, and allowed a moderate expansion of the 
number of transplant candidates, without impacting on post-transplant outcome in these 
retrospective studies (6, 9, 10).  
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The main limitation of the TTV/AFP criteria to date has been the lack of prospective 
validation. The present study was designed as a multicentric web-based prospective 
assessment of patients listed utilizing the TTV/AFP criteria, to support validation of these 
criteria for selection of HCC candidates for liver transplant. 
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Patients and Methods 
Study design 
The study was based on a web-based multicentric database, which prospectively includes 
data on patients with hepatocellular carcinoma listed for liver transplantation. In the 
present analysis, patients from the University of Alberta, Edmonton, Canada (starting 
January 2007), the University of Geneva, Geneva, Switzerland (starting October 2009), 
and the University of Western Ontario, London, Canada (starting January 2012) were 
analyzed, as these three centers used the previously described TTV/AFP criteria for 
candidate selection (9, 10). The composite criteria allowed access to listing for 
transplantation to patients with TTV ≤115 cm
3
 and AFP ≤400 ng/ml, in the absence of 
extra-hepatic disease and macrovascular HCC invasion on radiology (9, 10). All patients 
beyond the TTV/AFP cut-offs (whatever the level) were eligible for listing if they could 
be downstaged to within criteria according to mRECIST and stabilized within the criteria 
for a minimum of three months (11). Of note, only successfully downstaged patients were 
studied, as an accurate assessment of patients failing downstaging was difficult for 
geographical reasons (many who failed downstaging at distant centers were not referred 
for consideration of transplantation). A progression beyond TTV or AFP limits, while on 
the transplant waitlist, resulted in inactivation from the list. Inactivated patients 
considered suitable for locoregional therapy were offered further treatment. If responding 
and returning to within TTV/AFP criteria, and remaining stable for a minimum of 3 
months, they could be reactivated on the waitlist. A complete radiological response to 
loco-regional HCC treatment was not a delisting criterion. The database was updated 
until September 2014, but only patients listed prior to March 2013 were analyzed to 
Page 6 of 26
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
7 
 
allow sufficient follow-up. Four patients with non-cirrhotic underlying liver disease were 
excluded, because the selection of HCC liver transplant candidates without cirrhosis 
should be based on specific and different criteria, as size does not appear as a strong 
predictor of post-transplant outcome in this group of patients (12). The study was 
approved by the ethical review board of each institution. 
 
Collected data 
HCC data included listing, transplant and maximum levels for AFP and TTV. Only 
radiological assessments of HCC morphology were used throughout the study, as no 
pathological data is available for decision making at the time of listing and 
transplantation. TTV was calculated as the sum of the volume of each HCC ((4/3)πr
3
) 
based on the maximum radius of each lesion (9, 10). An HCC was diagnosed by arterial 
phase contrast enhancement and early venous phase washout on augmented CT or MRI, 
or by biopsy in cases with equivocal imaging studies, as outlined  in the AASLD 
guidelines (13).  
The use of pre-transplant HCC-directed treatment was recorded and included the use of 
trans-arterial chemoembolization (TACE), radio-frequency ablation (RFA), surgical 
resection, alcohol ablation and trans-arterial radioembolization (TARE).  Loco-regional 
treatments were used liberally in all eligible patients.  
Outcome variables included the date and cause of waitlist drop-out, post-transplant 
recurrence and death. Waitlist HCC monitoring included AFP and contrast enhanced 
triphasic CT or MRI assessments every three months, and 6 monthly bone scans. Post-
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transplant HCC monitoring included AFP, and CT or MRI imaging every six months for 
the first two years and yearly imaging thereafter. 
 
Analysis  
In order to assess the value of candidate selection based on the TTV/AFP score, patients 
within Milan criteria (and AFP <400 ng/ml) were used as the group of reference (3), and 
were compared to those beyond Milan, but within the TTV/AFP criteria. Patients within 
Milan included patients with a single tumor up to 5 cm in diameter or up to 3 tumors 
none larger than 3 cm (4). Of note, given the prospective study inclusion requirements 
included an AFP <400 ng/ml, the inclusion criteria excluded patients within Milan by 
morphological criteria but with AFP >400 ng/ml. As such, the “within Milan criteria” 
group in this prospective series was more highly selected than in standard practice, and so 
might be expected to have a better outcome. The two groups were compared regarding 
demographics, waitlist drop-out, intent-to-treat survival (from listing), post-transplant 
survival and post-transplant HCC recurrence. HCC characteristics of patients within vs 
beyond Milan were also represented graphically at listing and transplant as previously 
suggested (14). 
In an effort to capture the impact of HCC changes on post-transplant survival, patients 
were assessed at their peak levels and at the time of transplantation according to Milan 
criteria (within vs. beyond), TTV/AFP criteria (within vs. beyond), and AFP (≤ 400 
ng/ml vs. >400 ng/ml). Patients stable under the cut-off were compared to those 
downstaged from over the cut-off (peak) to below the cut-off at the time of transplant. 
Page 8 of 26
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
9 
 
Results were provided as mean ± standard deviation or median ± inter-quartile range 
(IQR) according to variable normality, which was assessed graphically. Groups were 
compared with the use of Student-t test, or Mann-Whitney test, and Chi-square test, or 
Fisher test according to normality. Survivals were displayed according to Kaplan Meier, 
and groups were compared with log-rank test. Standard alpha level of 0·05 indicated 
statistical significance. Analyses were conducted using SPSS 18·0 (SPSS, Chicago, IL).
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Results 
Listing characteristics 
During the study period, 233 patients with HCC were listed for liver transplantation 
(Table 1). They included 43 females and 190 males, with a mean age of 57,1 ±6,4 years. 
Cirrhosis was most often related to hepatitis C virus (HCV), hepatitis B virus (HBV) and 
alcohol. The mean calculated model for end-stage liver disease (MELD) score was 9,9 
±4,9. 
At the time of listing, 195 patients were within Milan criteria and 38 beyond Milan, but 
within TTV/AFP. Most patients had a limited number of small HCCs; the median AFP 
was 11 ±25 ng/ml (Table 1, Figure 1A). 
 
Risk of drop-out and intent-to-treat outcome 
Follow-up from listing was 33,9 ±24,9 months (median: 27,4 months, IQR: 29,8). At the 
time of writing, 166 (71%) patients had been transplanted, 65 (27%) had dropped from 
the list, one (1%) had been removed from the list (treated by TACE, without sign of 
recurrence after several years), and one (1%) was still active on the list. 
Drop-out was related to HCC progression (n=34), non-HCC related death (n=10) and 
deterioration of medical conditions considered beyond transplantable state (n=21). The 
overall risk of drop-out was significantly higher for patients beyond Milan but within 
TTV/AFP (16/38, 42,1%) than for patients within Milan (49/195, 25,1%, p=0.033). HCC 
progression was the most frequent cause of drop-out in both groups, and was nearly twice 
as frequent in patients beyond Milan but within TTV/AFP vs patients within Milan (9/38, 
21% vs 25/195, 12.8%, p=0.18, log-rank: p=0.082). Other causes of drop-out included 
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non-HCC related deaths (4/38, 10.5% vs. 6/195, 6.3%, p=0.038), and deterioration of 
medical conditions considered beyond transplantable state (2/38, 5.3% vs 6/195, 6.3%, 
p=0.5). Six and 12 months after listing, the rates of drop-out were 8,4 ±7,4 and 56,2 
±10,9% beyond Milan, but within TTV/AFP, and 10 ±2,3 and 18,9 ±3,4% within Milan 
(Figure 2A, log-rank, p<0,001). As expected from the drop-out rates, patients beyond 
Milan, but within TTV/AFP had significantly lower intent-to-treat survivals from listing 
than those within Milan (four-year survivals 53,8 ±10,1% vs. 71,6 ±3,9%, p<0,001, 
Figure 2B).  
 
Transplant characteristics and outcome 
Mean waiting time was 11,9 ±11,7 months (median: 8, IQR: 11), and was similar 
between patients within Milan vs. beyond Milan, but within TTV/AFP (12.4 ±12.3 vs 
10.5 ±8.7 months, p=0.40). Most patients underwent loco-regional treatment during this 
time, including TACE (n=135 patients), RFA (n=91), alcohol ablation (n=25) and 
surgical resection (n=15). The use of these treatments was not distributed differently 
between patients listed within Milan (169/195, 86,7%) and those beyond Milan, but 
within TTV/AFP (36/38, 94,7%, p=0,162). Of the 15 patients with surgical resection, 11 
had recurrent HCC present on pre-transplant imaging. Overall, both HCC size and 
number remained stable from listing until transplantation (in part because 33 patients 
with irreversible progression of TTV or AFP were dropped out), and most patients 
presented HCCs with only a limited expansion from Milan criteria (Table 1, Figure 1B). 
Of the transplanted patients, 56 patients demonstrated a complete pre-transplant 
radiological response, including 50/134 (37.3%) patients within Milan, and 6/32 (18.8%) 
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patients beyond Milan, but within TTV/AFP (0.046). Of all 56 patients with complete 
radiological response, 24 (43%) demonstrated no residual viable HCC on the explant.  
Of the 166 transplanted patients, 134 were within Milan and 32 beyond Milan, but within 
TTV/AFP at the time of transplantation. As expected, patients beyond Milan had larger 
and more numerous HCCs, and a trend towards higher AFP (Table 2). Of the 134 patients 
transplanted within Milan, 31 (23%) demonstrated HCCs beyond Milan on explants, 
most often because of a number of HCCs >3. 
Post-transplant follow-up was 30 ±22,1 months (median: 23,2, IQR: 32). Nine patients 
had recurrences, 8,5 to 45 months after transplantation, for a rate of recurrence of 5,4%. 
The most frequent sites of recurrence were the liver (n=4), lung (n=3), bone (n=1), spleen 
(n=1), peritoneum (n=1) and abdominal wall (n=1). Six patients with recurrence were 
within Milan (6/134, 4,5%) and three were beyond Milan but within TTV/AFP (3/32, 
9,4%, p=0,272). 
Post-transplant overall survivals were similar between patients within Milan (and with 
AFP <400 ng/ml), and patients beyond Milan, but within TTV/AFP (two-year survivals: 
86,1 ±3,5% vs 83,4 ±3,8%; four-year survivals: 78,7 ±4,9 vs 74,6 ±10,3%, p=0,932, 
Figure 2C). Post-transplant disease-free survivals were also similar between patients 
within Milan, and patients beyond Milan, but within TTV/AFP (two-year survivals: 83,4 
±3,8% vs 87,9 ±6,6%; four-year survivals: 77,9 ±4,7 vs 68,0 ±11,3%, p=0,930). 
 
Impact of TTV and AFP downstaging 
In order to assess the impact of downstaging, post-transplant survival was assessed 
according to the maximum observed tumor volumes and AFP. Patients beyond Milan at 
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any time, but downstaged to within Milan at the time of transplant (n=27) had similar 
post-transplant disease-free survivals as those continuously within Milan (n=101, two-
year survivals: 87,6 ±6,7% vs 81,7 ±4,5%; four-year survivals: 76,6 ±11,8 vs 78,1 ±5%, 
p=0,753, Figure 3A). Two recurrences appeared in patients downstaged to Milan (2/27, 
7,4%), and four in patients continuously within Milan (4/101, 4%, p=0,452). 
None of the 12 patients downstaged from beyond TTV/AFP and stabilized within 
TTV/AFP demonstrated a recurrence after a mean follow-up of 28,2 ±18,4 months (7 
patients were originally with AFP> 400 ng/ml and 5 were originally with TTV> 115 
cm
3
). They had similar post-transplant disease-free survivals as those continuously within 
TTV/AFP (n=154, two-year survivals: 100% vs 83,1 ±3,5%; four-year survivals: 100% 
vs 74,5 ±4,6%, p=0,140, Figure 3B).  
Seven of these patients had high peak AFP values between 412 and 5845 ng/ml and were 
successfully downstaged and stabilised at ≤400 ng/ml until the time of transplant. They 
were all alive and free of HCC recurrence after a mean follow-up of 29,5 ±18,7 months, 
and with similar post-transplant disease-free survivals as patients with AFPs continuously 
≤400 ng/ml (two-year survivals: 100% vs 83,7 ±3,6%; four-year survivals: 100 vs 74,7 
±4,8%, p=0,252, Figure 3C).
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Discussion 
The present prospective study suggests that HCC liver transplant candidate selection 
could be expanded to the TTV/AFP criteria in centers with at least 8-month median 
waiting times.  
 
These results confirm previous studies demonstrating similar post-transplant outcomes 
with the use of the TTV/AFP score as with Milan criteria, despite the inclusion of 
approximately 20% more patients (6, 9, 10). With a TTV cut-off of 115 cm3, any HCC 
size and number combination can be used, including patients with one HCC ≤6 cm, two 
HCCs ≤4,8 cm or three HCCs ≤4,2 cm. While some 30% more patients overall could be 
included based on HCC size and number compared to Milan, all patients with high AFPs 
(>400 ng/ml) were excluded, an important factor as these patients have been shown to 
have poor outcomes even when within Milan (15). This likely explains the very low 
tumor recurrence rate of 4,5% in the “Milan“ group in the present study. Our group of 
patients beyond Milan, but within TTV/AFP would compare even more favorably to a 
standard Milan group unselective for AFP.  
Of note, more patients were listed within Milan criteria (n=195) compared to the number 
of patients beyond Milan, but within TTV/AFP (n=38). Although we cannot exclude that 
some patients beyond Milan may have not been referred, or were missed internally, we 
consider this unlikely from the policy of discussing all stages of HCC in our 
multidisciplinary meetings. The balance between both groups is similar to the one of a 
previous population-based study (6), and probably corresponds to the fact that in units 
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serving a population where screening for HCC is well implemented, more patients are 
caught within Milan and with an AFP < 400, than beyond Milan, but within TTV/AFP.  
The originality and added value of the TTV/AFP score also lays in the absence of a strict 
cut-off by number of HCC, and a greater weighting for tumors of larger size. This leads 
to a more stringent selection of patients based on radiology, as HCC size (radius) is cubed 
in the calculation of volume, and larger lesions, unequivocally characterised by 
radiology, have more weight in the score (10). In other words, small, less than 1-cm 
lesions have minimal weight in including/excluding an individual from transplantation.  
Informal discussions with members of leading units reveal that ignoring a fourth or even 
a fifth lesion that is <1 cm is a relatively common practice in centers currently following 
“Milan” criteria.  
In practice, the current use of TTV/AFP criteria corresponds to the modest expansion of 
the “up to 7 without vascular invasion” advocated by the Metroticket study (1), by 
integrating similar size-volume limits, and by adding AFP as a surrogate marker for 
vascular invasion. The idea to combine morphological and biological factors has recently 
gained attraction with several centers reporting retrospective results of liver 
transplantation for patients with HCC (16-19). AFP >1000 ng/ml has been incorporated 
with morphological criteria by the UCSF liver transplant program (18).  
The expansion of morphological criteria due to the use of the TTV/AFP score led to 
higher rates of drop-out from the list and lower intent-to-treat survival rates. However, 
post-transplant outcomes were similar to what is currently accepted for non-HCC 
patients, suggesting non-HCC patients would not be penalized unfairly by the expansion 
in patients with HCC eligible for a graft. Because of the potential importance of the 
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waiting time to exclude patients with an aggressive tumor phenotype, the use of the 
TTV/AFP score cannot currently be recommended to centers with shorter waiting times 
than ours (close to 8 months). While waiting for specific data, a similar delay should also 
be advocated in case of living-donor liver transplantation, possibly in combination with 
aggressive loco-regional therapy: it is likely that the waiting time, before or after listing, 
allows exclusion of the more biologically unfavorable HCCs, especially within the group 
beyond Milan, and that early transplantation could worsen post-transplant outcomes (20). 
The present study included an aggressive wait-list loco-regional HCC management 
(33.7% of the transplanted patients demonstrated a complete radiological response), 
which might have contributed to the low incidence of post-transplant HCC recurrence. 
This policy also provided data on downstaging, as patients initially beyond the TTV/AFP 
criteria could be listed, provided they had been downstaged to within the limits and 
stabilized for a minimum of three months. Successfully downstaged patients with high 
peak AFPs (>400 ng/ml) had similar post-transplant HCC-free outcomes as those with 
stable low (≤400 ng/ml) AFPs. This observation, if confirmed, would validate previous 
registry-based data, suggesting that patients with transplant AFPs ≤400 ng/ml do well 
after transplantation, whatever the highest AFP level (15). Similarly, patients downstaged 
based on Milan criteria also demonstrated similar outcomes as those continuously within 
Milan. These data supports previous retrospective observations, and further reinforce the 
value of downstaging and the “ablate and wait” strategy (11, 21, 22).  
 
Altogether, the present prospective study shows that an expansion of HCC liver 
transplant candidate selection criteria to the TTV/AFP criteria achieves post-transplant 
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tumor-free survival equivalent to Milan criteria while allowing a 20% increase in the 
number of eligible patients. This observation was made in centers with median wait times 
of 8 months, and was accompanied by an increased rate of waitlist drop-out in the 
expanded group.  
We consider that the waitlist dropout as part of the selection process to achieve good long 
term results is a fair price to pay for equity in access to liver transplantation between 
HCC candidates and non-tumor candidates alike. The current report includes the first 
prospective series of patients transplanted after selection based on such combined 
morphological, biomarker and tumor-evolution criteria and argues for such a policy 
change. 
 
 
 
Acknowledgements 
Professor Gilles Mentha, MD, died unexpectedly on May 25, 2014, after bringing key 
input into the study. He was a world-renowned hepatobiliary and transplant surgeon, and 
professor of surgery at the Geneva University Hospital and Faculty of Medicine, 
Geneva, Switzerland. The authors pay tribute to his humane personality, clinical 
expertise, and scientific excellence. He was an example and a mentor.  
CT was supported by the Swiss National Science Foundation (PP00P3_139021). NMK 
was supported by the Capital Health Chair in Transplantation Research, University of 
Alberta. The study was supported by the University of Alberta Liver Transplant Program 
Page 17 of 26
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
18 
 
Academic Fund and the Artères Foundation. The authors have no conflict of interest to 
disclose. 
 
Page 18 of 26
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
19 
 
References 
1. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting 
survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan 
criteria: a retrospective, exploratory analysis. The lancet oncology. 2009;10(1):35-43. Epub 
2008/12/09. 
2. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five 
steps to prevent recurrence. American journal of transplantation : official journal of the 
American Society of Transplantation and the American Society of Transplant Surgeons. 
2011;11(10):2031-5. Epub 2011/08/13. 
3. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for 
liver transplantation for hepatocellular carcinoma: an international consensus conference 
report. The lancet oncology. 2012;13(1):e11-22. Epub 2011/11/04. 
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver 
transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. 
The New England journal of medicine. 1996;334(11):693-9. Epub 1996/03/14. 
5. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation 
for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact 
survival. Hepatology. 2001;33(6):1394-403. Epub 2001/06/08. 
6. Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients 
with hepatocellular carcinoma selected for liver transplantation using expanded selection 
criteria. Transplant international : official journal of the European Society for Organ 
Transplantation. 2009;22(9):869-75. Epub 2009/04/24. 
7. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. 
Role of immunosuppression and tumor differentiation in predicting recurrence after liver 
transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World journal 
of gastroenterology : WJG. 2006;12(45):7319-25. Epub 2006/12/05. 
8. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver 
Transplantation for Hepatocellular Carcinoma: A Model Including alpha-Fetoprotein Improves 
the Performance of Milan Criteria. Gastroenterology. 2012;143(4):986-94 e3. Epub 2012/07/04. 
9. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria 
prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of 
Transplant Recipients database. Hepatology. 2009;49(3):832-8. Epub 2009/01/20. 
10. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, et al. Total tumor volume 
predicts risk of recurrence following liver transplantation in patients with hepatocellular 
carcinoma. Liver transplantation : official publication of the American Association for the Study 
of Liver Diseases and the International Liver Transplantation Society. 2008;14(8):1107-15. Epub 
2008/08/01. 
11. Toso C, Mentha G, Kneteman NM, Majno P. The place of downstaging for hepatocellular 
carcinoma. Journal of hepatology. 2010;52(6):930-6. Epub 2010/04/14. 
12. Mergental H, Adam R, Ericzon BG, Kalicinski P, Muhlbacher F, Hockerstedt K, et al. Liver 
transplantation for unresectable hepatocellular carcinoma in normal livers. Journal of 
hepatology. 2012. Epub 2012/04/24. 
13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 
2005;42(5):1208-36. Epub 2005/10/27. 
14. Majno P, Mazzaferro V. Living donor liver transplantation for hepatocellular carcinoma 
exceeding conventional criteria: questions, answers and demands for a common language. Liver 
Page 19 of 26
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
20 
 
transplantation : official publication of the American Association for the Study of Liver Diseases 
and the International Liver Transplantation Society. 2006;12(6):896-8. Epub 2006/05/25. 
15. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al. The impact of 
waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular 
carcinoma. Journal of hepatology. 2011;55(4):814-9. Epub 2011/02/22. 
16. Grat M, Kornasiewicz O, Lewandowski Z, Holowko W, Grat K, Kobryn K, et al. 
Combination of morphologic criteria and alpha-fetoprotein in selection of patients with 
hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant 
tumor recurrence. World journal of surgery. 2014;38(10):2698-707. Epub 2014/05/27. 
17. Lee KW, Yi NJ, Suh KS. Section 5. Further expanding the criteria for HCC in living donor 
liver transplantation: when not to transplant: SNUH experience. Transplantation. 2014;97 Suppl 
8:S20-3. Epub 2014/05/23. 
18. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 
ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular 
carcinoma meeting the Milan criteria. Liver transplantation : official publication of the American 
Association for the Study of Liver Diseases and the International Liver Transplantation Society. 
2014;20(8):945-51. Epub 2014/05/07. 
19. Shindoh J, Sugawara Y, Nagata R, Kaneko J, Tamura S, Aoki T, et al. Evaluation methods 
for pretransplant oncologic markers and their prognostic impacts in patient undergoing living 
donor liver transplantation for hepatocellular carcinoma. Transplant international : official 
journal of the European Society for Organ Transplantation. 2014;27(4):391-8. Epub 2014/01/30. 
20. Halazun KJ, Patzer RE, Rana AA, Verna EC, Griesemer AD, Parsons RF, et al. Standing the 
test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, 
results of the UNOS natural geographic experiment. Hepatology. 2014. Epub 2014/06/24. 
21. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus 
rapid transplantation. Liver transplantation : official publication of the American Association for 
the Study of Liver Diseases and the International Liver Transplantation Society. 2010;16(8):925-
9. Epub 2010/07/27. 
22. Yao FY, Hirose R, LaBerge JM, Davern TJ, 3rd, Bass NM, Kerlan RK, Jr., et al. A prospective 
study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver 
transplantation : official publication of the American Association for the Study of Liver Diseases 
and the International Liver Transplantation Society. 2005;11(12):1505-14. Epub 2005/11/30. 
 
Page 20 of 26
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
21 
 
Figure legends 
Figure 1: Radiologically-assessed number of HCC and size of largest HCC for patients at 
listing (A, with or without drop-out for HCC progression) and at transplant (B, with or 
without post-transplant HCC recurrence). Grey lines show the size / number limits of 
Milan criteria. Some dots represent more than one patient. 
 
Figure 2: Drop-out rate (A, p<0.001), intent-to-treat (B, p<0.001) and overall (C, 
p=0.378) survivals for patients within Milan and beyond Milan, but within TTV/AFP 
 
Figure 3: Impact of Milan (A), TTV/AFP (B) and AFP (C, cut-off 400 ng/ml) 
downstaging on post-transplant disease-free survival.  
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Table 1: Patient and tumor characteristics at listing and transplant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Listing Transplant p
Patients (number) 233 166
Mean age (years ±SD) 57.1 ±6.4 57.6±6.5 0.41
Gender (ratio)
female:43/ 
male:190
female:25/ 
male:141 0.37
Cause of liver disease (%)
HCV (±alcohol, ±HBV) 142 (60) 102 (61) 0.912
HBV 28 (12) 20 (12) 0.99
Alcohol 35 (15) 24 (14) 0.878
NASH 12 (5) 8 (5) 0.883
Hemochromatosis 5 (2) 4 (2) 0.86
Other 14 (6) 10 (6) 0.993
Mean MELD score (±SD) 9.9 ±4.9 11.5±5.9 0.004
Median largest HCC diameter (cm ±IQR) 1.7 ±2.8 1.3 ±2.6 0.533
Median Total Tumor Volume (cm
3 
±IQR) 3.5 ±12.8 1.4 ±10.9 0.787
Median an number of HCC (±IQR) 1 ±2 1 ±2 0.437
Median serum alpha fetoprotein level (ng/ml ±IQR) 11 ±25 9 ±22 0.944
HCV: hepatitis C virus infection, HBV: hepatitis B virus infection
MELD: Model for End-Stage Liver Disease
NASH: non-alcoholic steato-hepatitis, HCC: hepatocellular carcinoma
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Table 2: Radiological pre-transplant characteristics within Milan and outside Milan,but within TTV/AFP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Within Milan
Beyond Milan, but 
within TTV/AFP p
Patients (number) 134 32
Median largest HCC diameter (cm ±IQR) 1 ±1.9 3.1 ±2 <0.001
Median Total Tumor Volume (cm
3 
±IQR) 0.5 ±4.2 21 ±43 <0.001
Median number of HCC (±IQR) 1 ±1 3 ±3 <0.001
Median serum alpha fetoprotein level (ng/ml ±IQR) 9 ±13 27 ±39 0.071
TTV: total tumor volume, AFP: alpha foeto-protein, HCC: hepatocellular carcinoma
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